Preventing Cancer Reproduction of Defective Cells

[Guest guest]

While studying one tumor-suppressing protein, Cheryl 's research team at

The University of Texas MD Cancer Center came across a separate

surprise. They found another protective protein known to work inside the cell

nucleus moonlighting out in the cell's cytoplasm.

Following up on this unexpected observation, they discovered the cancer-blocking

nuclear protein ATM has a second job controlling and killing damaged cells in

the area between the nucleus and the cell membrane. Both functions stymie cancer

by preventing reproduction of defective cells.

http://www.medicalnewstoday.com/articles/217341.php

***************************

Blood clots in the leg (deep vein thrombosis DVT) occur commonly. In one-half of

the cases, the blood clot will break loose and travel through the bloodstream to

the lungs which may be life-threatening. Current treatment stops the blood clot

from moving, but does not prevent permanent damage to the vein. Many patients

may suffer long-term swelling and pain in their legs.

Today, patients are normally treated with the blood-thinning medication warfarin

and must wear support hose for two years. A project led by Dr Per Morten

Sandset, a professor at Oslo University Hospital, and funded under the Research

Programme on Clinical Research (KLINISKFORSKNING) at the Research Council will

examine whether patients will benefit from additional treatment with drugs that

dissolve blood clots (a treatment called thrombolysis).

http://www.medicalnewstoday.com/articles/217734.php

*******************************************

Like a switch stuck in the on position, the bone marrow can churn out blood

cells that bloat internal organs and clog blood vessels, leading to

life-threatening disease.

Now University of Florida scientists have discovered a potential new drug that

can throw the switch on the runaway blood cell-production mechanism. The drug

shrinks cell-gorged organs and stems the overproduction of blood cells, and the

researchers are working toward bringing it into clinical trial in one year.

" The disease has a path it's going to take and you need to be able to alter that

path - our drug does that to a reasonable extent, " said P. Sayeski, Ph.D.,

an associate professor of physiology and functional genomics in the UF College

of Medicine, who led the research team.

http://www.medicalnewstoday.com/articles/217540.php

*********************************

FYI,

Lottie Duthu